NAD+ Precursors: Where the Human Data Actually Stops
Supplements raise blood NAD+ measurably. Whether that changes any outcome remains open.
Dr. Elena Vance
Chief of Research
Oct 4, 2026 • 10 min
What the data says
Blood NAD+
The endpoint most human trials report, which is a biomarker rather than a health outcome.
Source: Precursor supplementation trials
NAD+ declines with age in several tissues, and precursors such as nicotinamide riboside and nicotinamide mononucleotide raise blood levels reliably in human trials.
Raising a biomarker is not the same as changing an outcome. Trials to date have been short, small, and mostly reported blood NAD+, with functional endpoints inconsistent.
Tissue delivery is the unresolved question: blood levels may not reflect what reaches muscle or brain, which is where the rodent findings originated.
Short-term safety looks acceptable at studied doses. That is a different claim from benefit, and the marketing routinely blurs the two.
Editorial note: this article summarises published research for general information. It is not medical advice. Discuss any intervention with a qualified clinician.
